JERSEY CITY, N.J., Nov. 22, 2017 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovativeanti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the 29th Annual Piper Jaffray Healthcare Conference at the Lotte New York Palace Hotel on Tuesday,
A live webcast will be available on the investors section of the Company's website: www.SCYNEXIS.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.
About SCYNEXISSCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is the first representative of a novel intravenous and oral triterpenoid antifungal family and is in Phase 2 clinical development for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit www.scynexis.com.
Media RelationsCammy DuongMacDougall Biomedical CommunicationsTel: [email protected]
Investor RelationsSusan KimArgot PartnersTel: [email protected]
View original content:http://www.prnewswire.com/news-releases/scynexis-to-present-at-the-29th-annual-piper-jaffray-healthcare-conference-300560738.html
SOURCE SCYNEXIS, Inc.
Subscribe to our Free Newsletters!
Strokes occur when blood flow to an area of the brain is cut off. It is imperitive to detect the ...
Bile duct cancer occurs either within the liver or the point where the bile ducts emerge from the ...
Xeroderma pigmentosum is a rare inherited condition marked by extreme sensitivity to sunlight and ...View All